Primer probe, kit and method for detecting respiratory tract RNA virus

By providing specific primer probe combination and reverse transcription real-time fluorescence quantitative PCR method, the problem of insufficient multiple detection capabilities in the prior art is solved, and simultaneous detection of human metapneumovirus, respiratory syncytial virus and rhinovirus is achieved, simplifying the The experimental process was carried out and the detection efficiency was improved.

CN119020538APending Publication Date: 2024-11-26重庆市沙坪坝区疾病预防控制中心
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411348958.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-26
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

The existing single-weight RT-qPCR method has limited ability to detect multiple respiratory RNA viruses simultaneously, making it difficult to accurately and quickly identify respiratory viruses, especially human metapneumovirus, respiratory syncytial virus and rhinovirus.

Method used

Provide a primer probe and kit for detecting respiratory RNA viruses, including a combination of specific primer probes for human metapneumovirus, respiratory syncytial virus and rhinovirus, and adopts reverse transcriptional real-time fluorescence quantitative PCR method, which can Three viruses were detected simultaneously in one reaction, and signal labeling was performed using fluorescent reporter groups and fluorescent quenching groups to avoid contamination.

Benefits of technology

It realizes the simultaneous detection of human metapneumovirus, respiratory syncytial virus and rhinovirus in one reaction, simplifies experimental operations, improves detection efficiency, and shows good identification ability through specificity and sensitivity detection results.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119020538A_ABST
    Figure CN119020538A_ABST
Patent Text Reader

Abstract

The invention discloses a primer probe, a kit and a method for detecting respiratory tract RNA virus, and belongs to the technical field of medical diagnostics, the primer probe comprises upstream and downstream primers for detecting human metapneumovirus as shown in SEQ ID NO: 1 and SEQ ID NO: 2, a probe for detecting human metapneumovirus as shown in SEQ ID NO: 3, upstream and downstream primers for detecting respiratory syncytial virus as shown in SEQ ID NO: 4 and SEQ ID NO: 5, and a probe for detecting respiratory syncytial virus as shown in SEQ ID NO: 6; the upstream primer and the downstream primer for detecting the rhinovirus are respectively SEQ ID NO: 7 and SEQ ID NO: 8, and the probe for detecting the rhinovirus is SEQ ID NO: 9. The primer probe can specifically detect the human metapneumovirus, the respiratory syncytial virus and the rhinovirus, the detection efficiency is high, and the detection result is accurate.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of medical diagnosis, and in particular relates to a primer probe, a kit and a method for detecting respiratory RNA viruses. Background Art

[0002] Respiratory viral infections are common health problems worldwide, especially human metapneumovirus (HMPV), respiratory syncytial virus (RSV) and rhinovirus (RV), which are widely spread in the population. HMPV is a group of single-stranded negative-sense RNA viruses belonging to the family Paramyxoviridae. So far, two major genotypes (A and B) have been identified, which are further divided into four subgenotypes (A1, A2, B1 and B2) and two sublineages (A2a and A2b). It is one of the main pathogens causing acute respiratory infections in children and adults, especially in infants and immunocompromised patients. Symptoms of HMPV infection include fever, cough, laryngitis, bronchitis and pneumonia. RSV is a single-stranded negative-sense RNA virus belonging to the family Paramyxoviridae and is the main pathogen causing acute lower respiratory tract infections in infants and young children. RSV infection is usually high in winter and early spring. In addition to infants and young children, the elderly and immunocompromised individuals are also susceptible populations. Symptoms of RSV infection include runny nose, cough, wheezing and dyspnea. RV belongs to the family Picornaviridae and is the most common pathogen causing the common cold. RV includes three types: type A, type B and type C. The virus is mainly transmitted through airborne droplets and is common in autumn and spring. Symptoms of RV infection include runny nose, cough, sore throat and headache. Although the condition is generally mild, RV infection may cause serious lower respiratory tract diseases such as bronchitis and pneumonia in infants, the elderly and immunocompromised individuals. The infections caused by these viruses have similar clinical symptoms, so accurate and rapid identification of these three viruses is of great significance for clinical diagnosis and treatment. Although the existing single-plex RT-qPCR method is sensitive, it has limited ability to detect multiple viruses simultaneously in the same reaction. Therefore, there is an urgent need for an efficient multiplex detection method to solve this problem. Summary of the invention

[0003] In view of this, the object of the present invention is to provide a primer probe, a kit and a method for detecting respiratory RNA viruses.

[0004] In order to achieve the above object, the present invention provides the following technical solutions:

[0005] The present invention discloses a primer probe for detecting respiratory RNA viruses, wherein the primer probe is composed of a primer combination for detecting human metapneumovirus, respiratory syncytial virus, and rhinovirus;

[0006] The upstream and downstream primers for detecting human metapneumovirus are SEQ ID NO: 1 and SEQ ID NO: 2, respectively. The nucleotide sequence of SEQ ID NO: 1 is GAGAGAGTGCAGCAGATTCT, and the nucleotide sequence of SEQ ID NO: 2 is CTTAACCAGAACGTACTCTCTG. The probe for detecting human metapneumovirus is SEQ ID NO: 3, and the nucleotide sequence of SEQ ID NO: 3 is 5'-FAM-GAGGAACTCAGGCAGTGAAGTCCAAGT-BHQ1-3';

[0007] The upstream and downstream primers for detecting respiratory syncytial virus are SEQ ID NO: 4 and SEQ ID NO: 5, respectively. The nucleotide sequence of SEQ ID NO: 4 is CTTAGTGCACAATAGCACATCAC, and the nucleotide sequence of SEQ ID NO: 5 is GCTCCTTCACCTATGAATGC. The probe for detecting respiratory syncytial virus is SEQ ID NO: 6, and the nucleotide sequence of SEQ ID NO: 6 is 5'-ROX-TGCATGCTTCCTTGGCATCATAT-BHQ2-3';

[0008] The upstream and downstream primers for detecting rhinovirus are SEQ ID NO: 7 and SEQ ID NO: 8, respectively. The nucleotide sequence of SEQ ID NO: 7 is AAGGTGYGAAGAGCCSCGTGT, and the nucleotide sequence of SEQ ID NO: 8 is GAYGGRACCRACTACTTTGGGTG. The probe for detecting rhinovirus is SEQ ID NO: 9, and the nucleotide sequence of SEQ ID NO: 9 is 5'-HEX-ATCCTCCGGCCCCTGAAT-BHQ1-3'.

[0009] Furthermore, the 5' end of the probe is labeled with a fluorescent reporter group, and the fluorescent reporter signals of the probes do not interfere with each other; the 3' end of the probe is labeled with a fluorescent quencher group.

[0010] Furthermore, the fluorescent reporter group labeled at the 5' end of the primer probe for detecting human metapneumovirus is FAM; the fluorescent reporter group labeled at the 5' end of the primer probe for detecting respiratory syncytial virus is HEX; and the fluorescent reporter group labeled at the 5' end of the primer probe for detecting rhinovirus is ROX.

[0011] Furthermore, a kit for detecting respiratory RNA viruses is provided, the kit comprising the primer-probe combination according to any one of claims 1-3.

[0012] Furthermore, the kit also includes an enzyme mixture, a negative quality control product, a positive quality control product, and a PCR buffer; the enzyme mixture contains at least one of reverse transcriptase, Taq enzyme, UDG enzyme, magnesium ions, and dNTP.

[0013] Furthermore, the negative quality control product is pure water treated with ethylene glycol dipyrocarbonate; the positive quality control product is a plasmid containing specific sequences of three respiratory RNA viruses.

[0014] Furthermore, the detection method of reverse transcription real-time fluorescence quantitative PCR for respiratory RNA viruses comprises the following steps:

[0015] S1, extracting RNA from the sample to be tested;

[0016] S2, configuring a PCR amplification system containing a primer-probe combination to perform a reverse transcription real-time fluorescence quantitative PCR amplification reaction;

[0017] S3. Determine whether the corresponding respiratory RNA virus exists in the sample to be tested and determine the initial concentration of the respiratory RNA virus according to the amplification curve.

[0018] Furthermore, in the amplification system of step S2, the final concentration of the upstream primer is 0.1-1.0 μM, the final concentration of the downstream primer is 0.1-1.0 μM, and the final concentration of the probe is 0.05-0.25 μM.

[0019] Furthermore, the reverse transcription real-time fluorescence quantitative PCR reaction conditions are: reverse transcription at 55°C for 10 minutes, pre-denaturation at 95°C for 30 seconds;

[0020] Then, denaturation at 95°C for 10 seconds and annealing / extension at 60°C for 30 seconds were performed for a total of 40 cycles.

[0021] Furthermore, the sample to be tested is any substance containing respiratory RNA virus, including nasopharyngeal swabs and oropharyngeal swabs.

[0022] The beneficial effects of the present invention are:

[0023] 1. The present invention uses RNA as a template, can perform reverse transcription and PCR simultaneously in one reaction, and can simultaneously detect human metapneumovirus, respiratory syncytial virus, and rhinovirus in one reaction tube, effectively simplifying the experimental operation process and avoiding contamination caused by repeated opening of the lid.

[0024] Other advantages, objectives and features of the present invention will be described in the following description and will be apparent to those skilled in the art to some extent, or those skilled in the art may be taught from the practice of the present invention. The objectives and other advantages of the present invention may be realized and obtained through the following description. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] In order to make the purpose, technical solution and beneficial effects of the invention clearer, the present invention provides the following drawings for illustration:

[0026] Figure 1 In the specific detection experiment of the present invention, only the amplification curve of the human metapneumovirus gene template is added;

[0027] Figure 2 In the specific detection experiment of the present invention, only the amplification curve of the respiratory syncytial virus gene template is added;

[0028] Figure 3 In the specific detection experiment of the present invention, only the amplification curve of the rhinovirus gene template is added;

[0029] Figure 4 In the specific detection experiment of the present invention, only the amplification curve of the influenza A virus gene template is added;

[0030] Figure 5 In the specific detection experiment of the present invention, only the amplification curve of influenza B virus gene template is added;

[0031] Figure 6 In the specific detection experiment of the present invention, only the amplification curve of the novel coronavirus gene template is added;

[0032] Figure 7 Figure 1 shows the results of the human metapneumovirus sensitivity experiment;

[0033] Figure 8 The results of the respiratory syncytial virus sensitivity test of the present invention are shown in FIG.

[0034] Fig. 9 Figure 2 shows the results of the rhinovirus sensitivity test of the present invention. DETAILED DESCRIPTION

[0035] A primer probe, a kit and a method for detecting respiratory RNA viruses.

[0036] The nucleotide information of the primer probe provided by the present invention is shown in the following table. Table 1 Primer probe combination for detecting human metapneumovirus, respiratory syncytial virus, and rhinovirus. Unless otherwise specified, "HMPV" in Table 1 represents the human metapneumovirus primer probe set; "RSV" represents the respiratory syncytial virus primer probe set; "RV" represents the rhinovirus primer probe set; "F" represents the upstream primer; "R" represents the downstream primer; "P" represents the probe, and further, the 5' end of the probe in Table 1 is labeled with a fluorescent reporter group, and the 3' end of the probe is labeled with a fluorescent quencher group.

[0037] Table 1 Primer-probe combinations for human metapneumovirus, respiratory syncytial virus, and rhinovirus

[0038]

[0039] Establishment of RT-qPCR system for human metapneumovirus, respiratory syncytial virus and rhinovirus

[0040] S1. Acquisition of samples to be tested

[0041] S2. Extraction of RNA from the sample to be tested: Use a commercially available RNA extraction kit or a method well known to those skilled in the art to extract RNA from the sample to be tested.

[0042] S3. RT-qPCR amplification reaction: Take 5 μL of the above RNA extract as a template and add it to the RT-qPCR reaction mixture (the components of the reaction mixture are shown in Table 2). In the amplification system, the final concentration of the upstream primer is 0.4 μM, the final concentration of the downstream primer is 0.4 μM, and the final concentration of the probe is 0.2 μM; cover the tube tightly, centrifuge it instantly, put it into the amplification instrument, perform RT-qPCR amplification reaction according to the amplification program (as shown in Table 3), and read the fluorescence in the channels corresponding to FAM, HEX, and ROX, respectively.

[0043] Table 2 RT-qPCR reaction mixture components

[0044]

[0045]

[0046] Table 3 RT-qPCR amplification procedure

[0047]

[0048] The testing standards are as follows:

[0049] If there is no S-shaped curve in the amplification of the channels corresponding to FAM, HEX, and ROX, the sample is judged to be negative; if the amplification curve is obviously S-shaped and the CT value is ≤40, it is judged to be a positive sample;

[0050] The positive quality control and negative quality control provided in the kit are used for quality control in clinical trials, and the operation method is the same as that of the samples to be tested;

[0051] The quality control standards are as follows:

[0052] The amplification curve of the negative quality control product has no obvious S-shaped growth; the amplification curve of the positive quality control product is S-shaped; the above requirements must be met simultaneously in the same experiment, otherwise, the experiment will be considered invalid and must be repeated.

[0053] Kit-specific assays:

[0054] In the RT-qPCR amplification system, only human metapneumovirus gene template, respiratory syncytial virus gene template, and rhinovirus gene template were added at different concentrations, and only one respiratory virus gene template was added at a time, and RT-qPCR amplification was performed according to the method provided for establishing the RT-qPCR system as described above.

[0055] The results are as follows Figure 1-3 As shown, the test results show that when only a certain respiratory virus gene template is added, only the channel amplification curve corresponding to the respiratory virus presents an obvious S-shape, and there is no amplification in other channels. Therefore, the kit and detection method provided by the present invention can better distinguish the three respiratory viruses.

[0056] Influenza A virus, influenza B virus, and novel coronavirus, which are also respiratory RNA viruses, were selected as the viruses to be tested. Influenza A virus, influenza B virus, and novel coronavirus were added to the amplification system, respectively, and RT-qPCR amplification was performed according to the method provided for establishing the RT-qPCR system described above.

[0057] The results are as follows Figure 4-6 As shown, the amplification curve has no obvious S-shaped growth, indicating that the primer-probe combination provided by the present invention has no cross-reaction with other respiratory RNA viruses and has good specificity.

[0058] Kit sensitivity test

[0059] Take known concentrations of human metapneumovirus, respiratory syncytial virus, and rhinovirus positive plasmids and dissolve them in appropriate amount of ultrapure water. Calculate the number of copies per milliliter based on the molar mass of the plasmids, mix them in the same proportion, and then dilute them with ultrapure water to 1×10 7 copies / mL, 1×10 6 copies / mL, 1×10 5 copies / mL, 1×10 4 copies / mL, 1×10 3 copies / mL, 5×10 2 RT-qPCR amplification was performed according to the method provided in the above-mentioned RT-qPCR system. The results are as follows Figure 7-9 As shown:

[0060] The results of the human metapneumovirus sensitivity test are as follows Figure 7 Shown, FAM channel, three replicates, 5 × 10 2 copies / mL is negative;

[0061] The results of the respiratory syncytial virus sensitivity test are as follows Figure 8 Shown, ROX channel, three replicates, 5 × 10 2 copies / mL is negative;

[0062] The results of the rhinovirus sensitivity test are as follows Fig. 9 Shown, HEX channel, three replicates, 5 × 10 2 Copies / mL was negative.

[0063] Based on the above experimental results, the sensitivity of the detection kit for human metapneumovirus, respiratory syncytial virus and rhinovirus provided by the present invention is 1×10 3 copies / mL.

[0064] Finally, it should be noted that the above preferred embodiments are only used to illustrate the technical solutions of the present invention rather than to limit it. Although the present invention has been described in detail through the above preferred embodiments, those skilled in the art should understand that various changes can be made in form and details without departing from the scope defined by the claims of the present invention.

Claims

1. A primer probe for detecting respiratory RNA viruses, Features: The primer probe is composed of a combination of primers for detecting human metapneumovirus, respiratory syncytial virus, and rhinovirus; The upstream and downstream primers for detecting human metapneumovirus are SEQ ID NO: 1 and SEQ ID NO: 2, respectively. The nucleotide sequence of SEQ ID NO: 1 is GAGAGAGTGCAGCAGATTCT, and the nucleotide sequence of SEQ ID NO: 2 is CTTAACCAGAACGTACTCTCTG. The probe for detecting human metapneumovirus is SEQ ID NO: 3, and the nucleotide sequence of SEQ ID NO: 3 is 5'-FAM-GAGGAACTCAGGCAGTGAAGTCCAAGT-BHQ1-3'; The upstream and downstream primers for detecting respiratory syncytial virus are SEQ ID NO: 4 and SEQ ID NO: 5, respectively. The nucleotide sequence of SEQ ID NO: 4 is CTTAGTGCACAATAGCACATCAC, and the nucleotide sequence of SEQ ID NO: 5 is GCTCCTTCACCTATGAATGC. The probe for detecting respiratory syncytial virus is SEQ ID NO: 6, and the nucleotide sequence of SEQ ID NO: 6 is 5'-ROX-TGCATGCTTCCTTGGCATCATAT-BHQ2-3'; The upstream and downstream primers for detecting rhinovirus are SEQ ID NO: 7 and SEQ ID NO: 8, respectively. The nucleotide sequence of SEQ ID NO: 7 is AAGGTGYGAAGAGCCSCGTGT, and the nucleotide sequence of SEQ ID NO: 8 is GAYGGRACCRACTACTTTGGGTG. The probe for detecting rhinovirus is SEQ ID NO: 9, and the nucleotide sequence of SEQ ID NO: 9 is 5'-HEX-ATCCTCCGGCCCCTGAAT-BHQ1-3'.

2. A primer probe for detecting respiratory RNA viruses according to claim 1, Features: The 5' end of the probe for detecting human metapneumovirus, respiratory syncytial virus and rhinovirus is labeled with a fluorescent reporter group, and the fluorescent reporter signals of the probes do not interfere with each other; the 3' end of the probe for detecting human metapneumovirus, respiratory syncytial virus and rhinovirus is labeled with a fluorescent quenching group.

3. A primer probe for detecting respiratory RNA viruses according to claim 1, Features: The fluorescent reporter group labeled at the 5' end of the primer probe for detecting human metapneumovirus is FAM; The fluorescent reporter group labeled at the 5' end of the primer probe for detecting respiratory syncytial virus is HEX; The fluorescent reporter group labeled at the 5' end of the primer probe for detecting rhinovirus is ROX.

4. A kit for detecting respiratory RNA viruses, Features: The kit comprises the primer-probe combination according to any one of claims 1 to 3.

5. A kit for detecting respiratory RNA viruses according to claim 4, It is characterized in that The kit also includes an enzyme mixture, a negative quality control product, a positive quality control product, and a PCR buffer; the enzyme mixture contains at least one of reverse transcriptase, Taq enzyme, UDG enzyme, magnesium ions, and dNTP.

6. A kit for detecting respiratory RNA viruses according to claim 5, It is characterized in that The negative quality control product is pure water treated with ethylene glycol dipyrocarbonate; the positive quality control product is a plasmid containing specific sequences of three respiratory RNA viruses.

7. A method for detecting respiratory RNA viruses by reverse transcription real-time fluorescence quantitative PCR using the primer probe described in any one of claims 1 to 3, It is characterized in that The steps include: S1, extracting RNA from the sample to be tested; S2, configuring a PCR amplification system containing a primer-probe combination to perform a reverse transcription real-time fluorescence quantitative PCR amplification reaction; S3. Determine whether the corresponding respiratory RNA virus exists in the sample to be tested and determine the initial concentration of the respiratory RNA virus according to the amplification curve.

8. The method for detecting respiratory RNA viruses by reverse transcription real-time fluorescence quantitative PCR according to claim 7, It is characterized in that In the amplification system of step S2, the final concentration of the upstream primer is 0.1-1.0 μM, the final concentration of the downstream primer is 0.1-1.0 μM, and the final concentration of the probe is 0.05-0.25 μM.

9. The method for detecting respiratory RNA viruses by reverse transcription real-time fluorescence quantitative PCR according to claim 8, It is characterized in that The steps include: The reverse transcription real-time fluorescence quantitative PCR reaction conditions are: reverse transcription at 55°C for 10 minutes, pre-denaturation at 95°C for 30 seconds; Then, denaturation at 95°C for 10 seconds and annealing / extension at 60°C for 30 seconds were performed for a total of 40 cycles.

10. The method for detecting respiratory RNA viruses by reverse transcription real-time fluorescence quantitative PCR according to claim 9, It is characterized in that The sample to be tested is any substance containing respiratory RNA virus, including nasopharyngeal swabs and oropharyngeal swabs.